Advisory panel narrowly rejects oliceridine for acute pain

Advisory panel narrowly rejects oliceridine for acute pain

Source: 
BioCentury
snippet: 

FDA’s Analgesic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of oliceridine (TRV130) from Trevena Inc. (NASDAQ:TRVN) to manage moderate to severe pain in adults for whom IV opioids are warranted.